ArticleCEN case reports2019
Crohn's disease following rituximab treatment in a patient with refractory nephrotic syndrome.
Article in CEN case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Enhanced therapeutic efficacy of granulocyte/monocyte adsorption in rats with drug-induced colitis : Insights from a downsized bead column and newly formed B cells.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026Article
- Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide.Alimentary pharmacology & therapeutics · 2025Review
- Ocrelizumab-induced colitis-critical review and case series from a Romanian cohort of MS patients.Frontiers in neurology · 2025Article
- Successful Treatment of Rituximab-Induced Crohn's Disease With Ustekinumab.ACG case reports journal · 2024Article
- Cytokine Release Syndrome-Associated Colitis: Insights From a Case of Rituximab-Induced Pancolitis.ACG case reports journal · 2024Article
- Crohn's disease after multiple doses of rituximab treatment in a child with refractory nephrotic syndrome and anFrontiers in pediatrics · 2024Article
- An unusual cause of diarrhea in a child with nephrotic syndrome: Answers.Pediatric nephrology (Berlin, Germany) · 2023Article
- Rituximab-Induced Colitis and Esophagitis in a Patient With Granulomatosis With Polyangiitis.Cureus · 2023Article
- Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship withFrontiers in pharmacology · 2023Review
- B cell class switching in intestinal immunity in health and disease.Scandinavian journal of immunology · 2022Review
- Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective studyTurkish journal of medical sciences · 2021Article
- Rituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2021Review
- Targeting B cells for inflammatory bowel disease treatment: back to the future.Current opinion in pharmacology · 2020Review
- Crohn's Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review.Cancer research and treatment · 2020Review
- Rituximab Use in the Management of Childhood Nephrotic Syndrome.Frontiers in pediatrics · 2019Review
- De novo Inflammatory Bowel Disease in Kidney Transplant Recipients: A Single-Center Case Series Study.Inflammatory intestinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (RTX) is increasingly used for the treatment of refractory nephrotic syndrome due to its inhibitory effect on B cells which extends the period of remission, while lowering the dose of steroids needed for disease management. However, RTX can lead to various side effects, including Crohn's disease. Herein, we describe a case of a 15-year-old boy with refractory nephrotic syndrome diagnosed at age 9 years who developed Crohn's disease following RTX treatment. RTX was initiated in this patient at the age of 13 years 6 months due to occurrence of 12 relapses of nephrotic syndrome over a 4-year period, despite treatment using cyclosporine, steroid pulse therapy, and mycophenolate mofetil. The patient received 4 doses of RTX over a 2-year period (dose, 375 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.